Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Description
PRIMARY OBJECTIVES:
1. Evaluate for changes over time in the patients’ symptom experience,
2. Identify distinct symptom profiles over time.
3. Evaluate for demographic, clinical, environmental, and molecular risk factors associated with a worse profile.
OUTLINE:
Participants receiving ICI outside the scope of this study as part of usual care will have a chart review from the first cycle of non-investigational treatment for up to 4 cycles. Participants may complete symptom and health-related quality of life questionnaires during the course of the study, and blood samples will be obtained at regular clinic visits.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites